Transferable data exclusivity vouchers are not the solution to the antimicrobial drug development crisis : a commentary on the proposed EU pharma regulation
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
BMJ global health - 9(2024), 2 vom: 28. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Berner-Rodoreda, Astrid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Infective Agents |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 06.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjgh-2023-014605 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369134443 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369134443 | ||
| 003 | DE-627 | ||
| 005 | 20240306233047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjgh-2023-014605 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM369134443 | ||
| 035 | |a (NLM)38423550 | ||
| 035 | |a (PII)e014605 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berner-Rodoreda, Astrid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transferable data exclusivity vouchers are not the solution to the antimicrobial drug development crisis |b a commentary on the proposed EU pharma regulation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Health policy | |
| 650 | 4 | |a Health systems | |
| 650 | 4 | |a Infections, diseases, disorders, injuries | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 700 | 1 | |a Cobelens, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Vandamme, Anne-Mieke |e verfasserin |4 aut | |
| 700 | 1 | |a Froeschl, Günter |e verfasserin |4 aut | |
| 700 | 1 | |a Skordis, Jolene |e verfasserin |4 aut | |
| 700 | 1 | |a Renganathan, Elil |e verfasserin |4 aut | |
| 700 | 1 | |a t'Hoen, Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a Raviglione, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Jahn, Albrecht |e verfasserin |4 aut | |
| 700 | 1 | |a Bärnighausen, Till |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ global health |d 2016 |g 9(2024), 2 vom: 28. Feb. |w (DE-627)NLM262254549 |x 2059-7908 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:2 |g day:28 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjgh-2023-014605 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 2 |b 28 |c 02 | ||